Novel drug compositions and dosage forms of topiramate

• US 20050069587A1
• Filed: 08/31/2004
• Published: 03/31/2005
• Est. Priority Date: 09/02/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Gupta, Suneel Kumar, Modi, Nishit Bachulal
• Application Number:
  US10/930,917
• Publication Number:
  US 20050069587A1
• Time in Patent Office: Days
• US Class Current: 424/473
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and a solubilizing agent. The drug compositions of the present invention are particularly advantageous for use with low solubility and/or low dissolution rate pharmaceutical agents. The present invention is further directed to methods for manufacturing of said drug compositions and dosage forms. The present invention is further directed to methods of treatment comprising administration of said drug compositions and dosage forms. The present invention further provides topiramate drug compositions, dosage forms and methods of treatment which provide a reduction in the frequency and/or severity of at least one adverse event associated with topiramate treatment.

Claims

1. A drug composition comprising topiramate, wherein the topiramate is released at a substantially ascending rate of release upon administration of the drug composition to a subject.

2. A drug composition comprising topiramate, wherein the topiramate is released at rate which provides a substantially ascending drug plasma concentration upon administration of the drug composition to a subject.

3. A drug composition comprising topiramate and a solubilizing agent, wherein the topiramate is released at a rate which results in a reduction in the frequency or severity of at least one adverse event associated with topiramate treatment upon administration of the drug composition to a subject.

4. The drug composition of claim 3, wherein the solubilizing agent is a surfactant.

5. The drug composition of claim 4, wherein the surfactant is selected from LUTROL F127, polyoxyl 40 stearate or polyoxyl 50 stearate.

6. A dosage form comprising the drug composition of claim 3.

7. A dosage form comprising

(a) a core comprising a drug composition comprising topiramate and a solubilizing surfactant, and a push layer comprising an osmopolymer;

(b) a semi-permeable wall surrounding the core; and

(c) an exit orifice through the semi-permeable wall for releasing the drug composition from the dosage form over a prolonged period of time;

wherein the drug composition is released from the dosage form at a rate which results in a reduction in the frequency or severity of at least one adverse event associated with topiramate treatment upon administration of the dosage form to a subject.

8. A dosage form comprising

(a) a core comprising a first drug composition, a second drug composition and a push layer comprising an osmopolymer, wherein each of the first and second drug compositions comprise topiramate and an independently selected solubilizing agent;

(b) a semi-permeable wall surrounding the core; and

(c) an exit orifice through the semi-permeable wall for releasing the drug compositions from the dosage form over a prolonged period of time;

wherein the drug composition is released from the dosage form at a rate which results in a reduction in the frequency or severity of at least one adverse event associated with topiramate treatment upon administration of the dosage form to a subject.

9. A method of treating a disorder selected from the group consisting of epilepsy, migraine, glaucoma, ocular disorders, diabetic retinopathy, essential tremor, restless limb syndrome, obesity, weight loss, Type II Diabetes Mellitus, Syndrome X, impaired oral glucose tolerance, diabetic skin lesions, cluster headaches, neuralgia, neuropathic pain, diabetic neuropathy, elevated blood glucose levels, elevated blood pressure, elevated lipids, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, OCD, PTSD, ADHD, impulse control disorders, ALS, asthma, autism, autoimmune disorders, chronic neurodegenerative disorders, acute neurodegeneration, sleep apnea and sleep disorders or promoting wound healing in a subject in need thereof comprising administering to the subject a dosage form, wherein said dosage form comprises topiramate, and wherein the topiramate is released at a rate which results in a reduction of the frequency and/or severity of at least one adverse event associated with topiramate treatment.

10. A controlled release oral dosage form of topiramate for once-a-day administration to a subject comprising:

(a) A core comprising;

i. Topiramate;

ii. a structural polymer;

iii. a solubilizing surfactant;

(b) a semipermeable membrane at least partially surrounding the core; and

(c) an exit orifice through the semipermeable membrane which communicates with the core so as to allow release of the topiramate to the environment;

wherein the dosage form releases the topiramate over a prolonged period of time characterized by reduced cognitive impairment in the subject.

11. The controlled release oral dosage form of claim 10 adapted to release the topiramate at a substantially zero order release rate.

12. The controlled release oral dosage form of claim 10 adapted to release the topiramate at a substantially ascending release rate.

13. The controlled release oral dosage form of claim 10 wherein the reduced cognitive impairment is an improvement on controlled oral word association test.

14. The controlled release oral dosage form of claim 10 characterized by producing a substantially ascending blood plasma concentration of topiramate in the subject after a single dose over 24 hours.

15. A method for treating a condition responsive to topiramate comprising orally administering once a day to a subject a capsule shaped tablet core dosage form containing topiramate, a solubilizing surfactant and a pharmaceutically acceptable structural polymer carrier wherein the dosage form releases the topiramate at a substantially ascending release rate for a prolonged period of time.

16. The method of claim 15 wherein the dosage form contains about 50-60% topiramate, about 5-15% of a structural polymer carrier and about 15-40% of a solubilizing surfactant.

17. A capsule shaped tablet dosage form comprising a drug composition containing topiramate, a structural polymer carrier and a solubilizing surfactant wherein the dosage form, following oral administration to a subject, releases the active agent from the dosage form at a substantially ascending release rate for a prolonged period of time wherein the subject experiences reduced cognitive impairment.

18. The dosage form according to claim 17 wherein the composition comprises about 50-60% of topiramate, about 5-15% of a structural polymer carrier and about 15-40% of a solubilizing surfactant.

19. The dosage form according to claim 18 comprising:

a capsule shaped tablet core containing a plurality of layers wherein the drug composition is contained in at least one layer and at least one other layer comprises a suitable fluid-expandable polymer;

a semipermeable membrane surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment; and

an orifice formed through the semipermeable membrane and into the capsule shaped tablet core to permit topiramate to be released from within the compartment into the external fluid environment.

20. The dosage form according to claim 19, wherein the capsule shaped tablet core comprises three layers and a portion of the topiramate drug composition is contained within a first layer and the remaining portion of the topiramate drug composition is contained within a second layer, wherein the portion of topiramate contained within the first layer is less than the portion of topiramate contained within the second layer, and wherein the fluid-expandable polymer is contained within a third layer and the orifice is formed through the semipermeable membrane adjacent the first layer.

21. A method for treating a condition responsive to topiramate comprising administering once a day to a subject the capsule shaped tablet dosage form of claim 20.